

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

**LIMITED REVIEW REPORT AND
THE INTERIM CONDENSED SEPARATE
FINANCIAL STATEMENTS
FOR THE SIX MONTHS PERIOD ENDED
30 JUNE 2025**

CLEOPATRA HOSPITAL “S.A.E.”

**Interim condensed separate financial statements
For the six months period ended 30 June 2025**

Index	Page
Limited review report	1
Interim condensed separate statement of financial position	2
Interim condensed separate statement of profits or losses	3
Interim condensed separate statement of comprehensive income	4
Interim condensed separate statement of changes in equity	5
Interim condensed separate statement of cash flows	6
Notes to the interim condensed separate financial statements	7 - 25

Limited Review Report On the Interim Financial Statements

To The Board of Directors of Cleopatra Hospital Company (S.A.E.)

Introduction


We conducted our limited review on the accompanying interim condensed separate financial position of Cleopatra Hospital Company (S.A.E.) (the "Company") as at 30 June 2025 and the related interim condensed separate statements of profit or loss, comprehensive income, changes in equity and cash flows for the six months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed separate financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed separate financial statements based on our limited review.

Scope of the limited review


We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed separate financial statements consists of applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed separate financial statements.

Conclusion

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed separate financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".



Mohamed Elsawaf
Member of Egyptian Society of Accountants & Auditors
R.A.A. 39521
F.R.A. 419



28 August 2025
Cairo

CLEOPATRA HOSPITAL COMPANY "S.A.E."

Interim condensed separate statement of financial position – At 30 June 2025

(All amounts are shown in Egyptian Pounds)	Note	30 June 2025	31 December 2024
Non-current assets			
Fixed assets	5	976,125,262	818,165,055
Right-of-use assets	6	29,774,910	31,343,663
Goodwill		158,516,300	158,516,300
Investments in subsidiary	7	1,937,663,845	1,622,658,845
Investments in associates	8	2,449,990	2,449,990
Total non-current assets		3,104,530,307	2,633,133,853
Current assets			
Inventories	9	94,203,933	102,914,463
Trade and other receivables	10	464,082,053	367,607,947
Due from related parties	23	244,596,579	155,787,321
Debtors and other debit balances	11	169,732,509	178,468,715
Cash and cash equivalents	12	81,058,934	169,956,870
Total current assets		1,053,674,008	974,735,316
Total assets		4,158,204,315	3,607,869,169
Equity			
Share capital		722,717,101	722,717,101
Treasury Shares	25	(5,589,873)	(5,589,873)
Retained earnings		1,364,089,444	1,254,673,621
Employees stock ownership Plan		96,466,936	36,466,936
Reserves		209,425,348	188,823,089
Total equity		2,387,108,956	2,197,090,874
Liabilities			
Non-current liabilities			
Lease liabilities	16	27,784,400	30,526,476
Loans	13	294,600,000	271,340,272
Deferred tax liabilities		20,129,992	13,169,967
Total non-current liabilities		342,514,392	315,036,715
Current liabilities			
Bank overdrafts	14	328,009,587	302,160,797
Provisions		46,547,756	55,649,444
Trade and other payables	15	592,839,639	402,066,373
Due to related parties	23	297,378,831	147,201,866
Loans	13	73,650,000	67,835,068
Lease liabilities	16	14,223,661	12,380,013
Other liabilities		4,485,000	4,485,000
Current income tax liabilities		71,446,493	103,963,019
Total current liabilities		1,428,580,967	1,095,741,580
Total liabilities		1,771,095,359	1,410,778,295
Total equity and liabilities		4,158,204,315	3,607,869,169

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

Mr. Ahmed Adel Badreldin
Non Executive Chairman

Dr. Ahmed Ezz Eldin Mahmoud
CEO & Managing Director

Mr. Mohamed Omar Al-Farouk
Group Finance Director

28 August 2025
Limited review report attached



CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Interim condensed separate statement of profit or loss For the six months ended 30 June 2025

(All amounts are shown in
Egyptian Pounds)

		Six months ended 30 June		Three months ended 30 June	
	Note	2025	2024	2025	2024
Revenue	17	1,275,057,180	940,658,715	675,055,634	476,997,889
(Less)					
Cost of revenue	18	(715,149,914)	(530,880,073)	(378,983,334)	(271,365,868)
Gross profit		559,907,266	409,778,642	296,072,300	205,632,021
Add / (Less)					
General and administrative expenses	19	(164,770,676)	(128,389,734)	(86,022,744)	(71,262,826)
Impairment of financial assets	20	(8,502,108)	(9,287,587)	(2,492,515)	(5,267,967)
Other income (Expenses)		(682,933)	8,034,734	(1,632,232)	8,344,337
Operating profit		385,951,549	280,136,055	205,924,809	137,445,565
Acquisition costs		(330,000)	-	-	515,500
Finance income		7,675,739	13,734,752	3,068,729	4,134,220
Finance cost		(57,105,125)	(43,865,028)	(29,264,595)	(24,966,142)
Profit for the period before income tax		336,192,163	250,005,779	179,728,943	117,129,143
Current tax		(79,373,768)	(52,142,277)	(44,016,622)	(30,857,835)
Deferred tax		(6,960,025)	(7,896,417)	2,224,084	2,788,674
Net profits for the period		249,858,370	189,967,085	137,936,405	89,059,982
Earnings per share (Basic/Diluted)	21	0.17	0.13	0.10	0.06

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Interim condensed separate statement of comprehensive income
For the six months ended 30 June 2025

(All amounts are shown in
Egyptian Pounds)

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Profit for the period	249,858,370	189,967,085	137,936,405	89,059,982
Other comprehensive income	-	-	-	-
Comprehensive income for the period	249,858,370	189,967,085	137,936,405	89,059,982

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Interim condensed separate statement of changes in equity - For the six months period ended 30 June 2025

(All amounts in Egyptian Pounds)	Share capital	Treasury Shares	Reserves	Retained earnings	Employees' stock ownership plan	Total equity
Balance at 1 January 2024	722,717,101	(5,051,601)	171,962,629	926,705,520	16,076,585	1,832,410,234
Dividends for employees and board of directors	-	-	-	(70,952,067)	-	(70,952,067)
Employees stock ownership Plan	-	-	-	-	35,136,937	35,136,937
Reserves	-	-	13,125,024	(13,125,024)	-	-
Treasury shares	-	(16,812,126)	-	-	-	(16,812,126)
Comprehensive income for the period	-	-	-	189,967,085	-	189,967,085
Balance at 30 June 2024	722,717,101	(21,863,727)	185,087,653	1,032,595,514	51,213,522	1,969,750,064
Balance at 1 January 2025	722,717,101	(5,589,873)	188,823,089	1,254,673,621	36,466,936	2,197,090,874
Dividends for employees and board of directors	-	-	-	(119,840,288)	-	(119,840,288)
Employees stock ownership Plan	-	-	-	-	60,000,000	60,000,000
Reserves	-	-	20,602,259	(20,602,259)	-	-
Comprehensive income for the period	-	-	-	249,858,370	-	249,858,370
Balance at 30 June 2025	722,717,101	(5,589,873)	209,425,348	1,364,089,444	96,466,936	2,387,108,956

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Interim condensed separate statement of cash flows For the six months period ended 30 June 2025

(All amounts in Egyptian Pounds)	Note	30 June 2025	30 June 2024
Cash flows from operating activities			
Profit before income tax		336,192,163	250,005,779
Adjustments to settle net profit with cash flow from operating activities			
Fixed assets depreciation	5	36,461,800	27,648,276
Right of use assets depreciation	6	4,535,298	4,386,332
Loss from sale of fixed assets		(1,939,474)	(304,954)
Impairment of trade and other receivables	10	8,502,109	9,287,587
Impairment of inventory	9	410,191	178,819
Provisions		6,700,189	5,620,427
Interests and commissions - Overdraft		54,349,781	41,016,523
Interests and commissions - Lease		2,755,344	2,848,505
Interest income		(5,580,451)	(4,752,146)
Employees stock ownership Plan		60,000,000	35,136,937
Operating profits before changes in assets and liabilities		502,386,949	371,072,085
Changes in assets and liabilities			
Change in inventories		8,300,339	8,427,349
Change in trade receivables		(105,165,407)	(138,027,920)
Change in debtors and other debit balances		8,736,206	(1,020,225)
Change in due from related parties		(88,809,258)	(949,379)
Change in creditors and other credit balances		190,773,265	47,208,504
Change in due to related parties		150,176,965	(16,608,094)
Change in working capital		666,399,060	270,102,320
Provision utilized		(15,801,877)	(8,417,427)
Tax paid		(111,890,293)	(44,531,157)
Net cash generated from operating activities		538,706,890	217,153,736
Cash flows from investing activities			
Payments for purchase of fixed assets		(9,225,430)	(56,139,465)
Payments for projects under construction		(185,196,577)	(90,425,289)
Proceeds from sale of fixed assets		1,939,474	415,696
Advance payment for purchase of fixed assets		-	(44,239,702)
Payments under long-term investments		(315,005,000)	(100,002,000)
Interests received		5,580,451	4,752,146
Net cash from used in investing activities		(501,907,082)	(285,638,614)
Cash flows from financing activities			
Lease liabilities payments		(6,620,317)	(6,024,942)
Proceeds from bank overdraft		730,980,735	671,229,524
Payments for bank overdraft		(705,131,945)	(599,449,306)
Proceeds from loans		38,824,660	108,029,466
Payments for loans		(9,750,000)	(9,750,000)
Interests and commissions paid		(54,349,781)	(43,865,028)
Treasury shares		-	(16,812,126)
Dividends paid		(119,840,288)	(70,952,067)
Net cash from used in financing activities		(125,886,936)	32,405,521
Changed in cash and cash equivalents during the period		(89,087,128)	(36,079,357)
Cash and cash equivalents at the beginning of the period		170,924,146	73,897,240
Cash and cash equivalents at the end of the period	12	81,837,018	37,817,883

The accompanying notes from 1 to 25 are integral part of these separate interim condensed financial statements.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

1. Introduction

Cleopatra Hospital Company (Lasheen and Partners) was established as a limited partnership on 19 July 1979 and is located in the Arab Republic of Egypt. The decision of the Chairman of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of Cleopatra Hospital (Lasheen and Partners) from a "limited partnership" into Cleopatra Hospital Company " S.A.E." in accordance with law no.95 of 1992.

The company is listed on the Egyptian Stock Exchange.

1-1 Principal activity, The Company's purpose is to establish a private hospital to provide advanced modern health and medical services, as well as the medical care of inpatients. The Company may have interest or participate in any manner in companies or other firms which carry on similar activities in Egypt or abroad. The Company may acquire, merge or affiliate such entities under the General Authority for Investment. The Separate financial statements representing in three Hospitals (Cleopatra Hospital, Queens Hospital and Elkateb Hospital).

1-2 Registered address and place of business

The Company is located at 39, 41 Cleopatra Street, Heliopolis, Cairo.

These separate financial statements were approved for issuance by the Board of Directors of the Company on 28 August 2025.

2. Basis of preparation

2.1 Statement of compliance

This interim condensed separate financial statements for the six-month reporting period ended 30 June 2025 have been prepared in accordance with Egyptian Accounting Standard 30 “Interim Financial Reporting”.

This interim condensed separate financial information does not include all the notes normally included in an annual financial statement. Accordingly, this interim condensed separate financial information is to be read in conjunction with the separate annual financial statement for the year ended 31 December 2025.

The accounting policies adopted in the preparation of this interim condensed separate financial information are consistent with those of the previous financial year and corresponding interim reporting period.

The business results for the six months ending at June 30, 2025 are not necessarily indicative of the business results for the fiscal year ending at December 31, 2025.

2.2 Functional and presentation currency

Items included in the interim condensed separate financial statements are measured using the currency of the primary economic environment in which the Company operates (‘the functional currency’). The Company's interim condensed separate financial statements are presented in Egyptian Pounds, which is the Company’s functional and presentation currency.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

2. Basis of preparation (continued)

2.3 Use of estimates and judgements

The preparation of interim condensed separate financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expenses. Actual results may differ from these estimates.

The significant judgments made by management in applying the Company's accounting policies and key sources of estimation uncertainty were the same as those described in the last separate financial statements as at and for the year ended 31 December 2024.

3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Company. The senior management is represented in Company's executive management committee. The segment reports are provided to the Company based on each company, as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the year ended 30 June 2025 for each segment:

	Cleopatra Hospital Company	Al Kateb Hospitals	Consolidated adjustment	Total
Statement of financial position				
Non-current assets	2,918,721,335	185,808,972	-	3,104,530,307
Current assets	1,047,630,997	107,996,401	(101,953,390)	1,053,674,008
Total assets	3,966,352,332	293,805,373	(101,953,390)	4,158,204,315
Current liabilities	1,403,792,690	126,741,667	(101,953,390)	1,428,580,967
Non-current liabilities	338,224,375	4,290,017	-	342,514,392
Total Liabilities	1,742,017,065	131,031,684	(101,953,390)	1,771,095,359
Statement of profit or loss:				
revenue	1,109,112,121	165,945,059	-	1,275,057,180
Cost of revenue	(606,080,844)	(109,069,070)	-	(715,149,914)
Gross profit	503,031,277	56,875,989	-	559,907,266
Other expenses and revenues	(275,407,557)	(34,641,339)	-	(310,048,896)
Profit for period	227,623,720	22,234,650	-	249,858,370
Other Items				
Capital expenditure	178,675,718	15,746,289	-	194,422,007
Fixed assets depreciation	30,212,164	6,249,636	-	36,461,800

* Consolidation constraints are mainly the exclusion of balances and transactions between CGUs.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

3. Segment reporting (continued)

Below is a summary of each segment, which is presented for the year ended 31 December 2024 for each segment:

	Cleopatra Hospital	El Kateb Hospital	Consolidation restrictions	Total
Statement of financial position				
Non-current assets	2,460,878,342	172,255,511	-	2,633,133,853
Current assets	991,536,690	69,016,175	(85,817,549)	974,735,316
Total assets	3,452,415,032	241,271,686	(85,817,549)	3,607,869,169
Current liabilities	1,083,990,200	97,568,929	(85,817,549)	1,095,741,580
Non-current liabilities	311,872,997	3,163,718	-	315,036,715
Total liabilities	1,395,863,197	100,732,647	(85,817,549)	1,410,778,295
Statement of profit or loss:				
Operating income	1,909,579,511	238,265,538	-	2,147,845,049
Cost of obtaining revenue	(1,018,572,568)	(177,309,404)	-	(1,195,881,972)
Gross profit	891,006,943	60,956,134	-	951,963,077
Other income and expenses	(491,111,830)	(48,806,055)	-	(539,917,885)
Profit for the year	399,895,113	12,150,079	-	412,045,192
Other items				
Capital expenditures	307,004,166	21,086,194	-	328,090,360
Depreciation of fixed assets	48,113,212	8,905,364	-	57,018,576

* Consolidation constraints are mainly the exclusion of balances and transactions between CGUs.

Below is a summary of each segment, which is presented for the year ended 30 June 2024 for each segment:

	Cleopatra Hospital Company	Al Kateb Hospitals	Consolidated adjustment	Total
Statement of financial position				
Non-current assets	2,077,208,269	168,231,356	-	2,245,439,625
Current assets	746,605,007	50,305,164	(84,781,237)	712,128,934
Total assets	2,823,813,276	218,536,520	(84,781,237)	2,957,568,559
Current liabilities	781,566,642	82,050,493	(84,781,237)	778,835,898
Non-current liabilities	205,538,401	3,444,196	-	208,982,597
Total Liabilities	987,105,043	85,494,689	(84,781,237)	987,818,495
Statement of profit or loss:				
Revenue	836,384,008	104,274,707	-	940,658,715
Cost of revenue	(453,122,935)	(77,757,138)	-	(530,880,073)
Gross profit	383,261,073	26,517,569	-	409,778,642
Other expenses and revenues	(197,946,859)	(21,864,698)	-	(219,811,557)
Profit for period	185,314,214	4,652,871	-	189,967,085
Other Items				
Capital expenditure	133,012,082	13,552,672	-	146,564,754
Fixed assets depreciation	21,935,353	5,712,923	-	27,648,276

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

4. Financial assets and financial liabilities

The Company holds the following financial instruments:

	Amortized cost	
	30 June 2025	31 December 2024
Financial assets		
Trade receivables	532,411,717	427,246,310
Due from related parties	244,596,579	155,787,321
Debtors and other debit balances *	70,289,539	62,839,227
Cash on hand and at banks	81,837,018	170,924,146
	929,134,853	816,797,004

* Excluding prepayments, advances to suppliers, and withholding taxes.

	Amortized cost	
	30 June 2025	31 December 2024
Financial Liabilities		
Creditors and other credit balances **	588,031,790	283,231,914
Loans	368,250,000	339,175,340
Bank's overdraft	328,009,587	302,160,797
Due to Related Parties	297,378,831	147,201,866
Lease liabilities	42,008,061	42,906,489
	1,623,678,269	1,114,676,406

** Excluding social insurance.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements - For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

5. Fixed assets

	Lands	Machinery, equipment and devices	Tools and instruments	Furniture	Buildings	Vehicles	Computers	Leasehold improvements	Projects under construction	Total
At 1 January 2024										
Cost	82,878,000	279,445,633	21,744,157	34,717,716	97,061,949	27,955,145	62,751,336	42,647,406	177,052,901	826,254,243
Accumulated depreciation	-	(138,257,865)	(10,015,842)	(17,373,468)	(39,875,866)	(6,285,797)	(46,005,871)	(21,103,726)	-	(278,918,436)
Net book value	82,878,000	141,187,768	11,728,315	17,344,248	57,186,083	21,669,348	16,745,464	21,543,680	177,052,901	547,335,807
Year ended 31 December 2024										
Opening net book value	82,878,000	141,187,768	11,728,315	17,344,248	57,186,083	21,669,348	16,745,464	21,543,680	177,052,901	547,335,807
Additions	-	48,504,794	3,725,104	6,095,674	-	10,440,000	1,603,338	-	257,721,450	328,090,360
Disposals	-	(939,863)	(630,482)	(1,170,266)	(320,791)	(860,550)	(24,834)	-	-	(3,946,786)
Transfers from projects under construction	-	2,599,434	56,722	1,457,363	145,186,468	-	2,411,719	1,174,058	(152,885,764)	-
Depreciation for the year	-	(24,588,788)	(2,372,581)	(5,291,704)	(4,790,573)	(5,145,897)	(9,381,781)	(5,447,252)	-	(57,018,576)
Accumulated depreciation of disposal	-	920,428	566,755	1,142,686	202,036	860,550	11,795	-	-	3,704,250
Balance at 31 December 2024	82,878,000	167,683,773	13,073,833	19,578,001	197,463,223	26,963,451	11,365,701	17,270,486	281,888,587	818,165,055
At 31 December 2024										
Cost	82,878,000	329,609,998	24,895,501	41,100,487	241,927,626	37,534,595	66,741,558	43,821,468	281,888,587	1,150,397,820
Accumulated depreciation	-	(161,926,225)	(11,821,668)	(21,522,486)	(44,464,403)	(10,571,144)	(55,375,857)	(26,550,982)	-	(332,232,765)
Net book amount	82,878,000	167,683,773	13,073,833	19,578,001	197,463,223	26,963,451	11,365,701	17,270,486	281,888,587	818,165,055
At 30 June 2025										
Opening net book value	82,878,000	167,683,773	13,073,833	19,578,001	197,463,223	26,963,451	11,365,701	17,270,486	281,888,587	818,165,055
Additions	-	3,116,475	698,662	2,571,984	-	-	2,838,309	-	185,196,577	194,422,007
Disposals	-	(828,686)	(182,447)	(429,602)	-	-	(649,789)	-	-	(2,090,524)
Transfers from projects under construction	-	7,112,928	4,035,210	426,300	-	-	217,564	-	(11,792,002)	-
Depreciation for the period	-	(13,530,835)	(1,330,600)	(2,751,764)	(10,060,502)	(2,612,084)	(3,531,037)	(2,644,978)	-	(36,461,800)
Accumulated depreciation of write-off	-	828,686	182,447	429,602	-	-	649,789	-	-	2,090,524
Balance at 30 June 2025	82,878,000	164,382,341	16,477,105	19,824,521	187,402,721	24,351,367	10,890,537	14,625,508	455,293,162	976,125,262
Cost	82,878,000	339,010,715	29,446,926	43,669,169	241,927,626	37,534,595	69,147,643	43,821,464	455,293,162	1,342,729,300
Accumulated depreciation	-	(174,628,374)	(12,969,821)	(23,844,648)	(54,524,905)	(13,183,228)	(58,257,106)	(29,195,956)	-	(366,604,038)
Net book value at period end	82,878,000	164,382,341	16,477,105	19,824,521	187,402,721	24,351,367	10,890,537	14,625,508	455,293,162	976,125,262

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

6. Right-of-use assets

The Egyptian Standard No, (49) “Leasing Contracts” has been applied in two phases as follows:

The first stage relates to lease contracts that were subject to Law (95) for the year 1995 starting on or after 1 January 2019, which are lease contracts related to medical equipment and measured at the beginning of the contract at a value equal to the value of the lease obligations in addition to rental expenses and subsequently depreciated over the life of the lease contracts using the straight-line method.

The second phase represents lease contracts related to buildings that were subject to Law (95) for the year 1995 starting on or after 1 January 2021 and measured at a carrying amount as if the standard had been applied since inception of the lease but discounted using the lending rate to the lessee at the date of application, and it is subsequently depreciated over the life of the lease using the straight-line method.

	30 June 2025	31 December 2024
Buildings		
Beginning balance for the period/ year	31,343,663	40,065,279
Adjustments	-	140,149
Additions for the period/ year	2,966,545	-
Depreciation for the period/ year	(4,535,298)	(8,861,765)
Total	29,774,910	31,343,663

Lease payments are discounted using the interest rate implicit in the lease contract, if this rate cannot be determined, then the borrowing rate of the lessee is used, which is the rate that the lessee would have to pay to borrow the money needed to obtain an asset of similar value in a similar economic environment with similar terms and conditions. An average interest rate of 11.15% has been used.

7. Investments in subsidiaries

	Investment Percentage	Country	30 June 2025	31 December 2024
Investment in CHG SKY*	99.99%	Egypt	800,013,700	485,008,700
Investments in Nile Badrawi Hospital Company	99.989%	Egypt	380,004,947	380,004,947
Investments in Al shorouk Hospital Company	99.999%	Egypt	374,142,000	374,142,000
Investments in Cairo Specialised Hospital Company	%57.01	Egypt	153,712,998	153,712,998
Investments in El Bedaya El Gedida for Medical Centers and Hospitals Company	99.99%	Egypt	119,482,000	119,482,000
Investments in CHG for hospitals Company	99.99%	Egypt	30,000,000	30,000,000
Investments in CHG Pharma for Pharmacies Management Company	98%	Egypt	245,000	245,000
Investments in CHG for Medical Services Company	20% (Preferred shares)	Egypt	62,500	62,500
Investment in Heaven Company	99.99%	Egypt	80,000,700	80,000,700
			1,937,663,845	1,622,658,845

* The capital of CHG Sky Hospital Company "S.A.E." has been increased by 315 million Egyptian pounds until June 30, 2025, so that the capital becomes 800,013,700 on June 30, 2025.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

8. Investments in associates:

	30 June 2025	31 December 2024
Egypt Healthcare Facilities Services for facility management	2,449,990	2,449,990
	2,449,990	2,449,990

9. Inventories

	30 June 2025	31 December 2024
Medical supply inventory	50,023,491	59,196,895
Medicine inventory	39,877,405	40,152,107
Maintenance and spare parts inventory	2,514,268	2,172,416
Stationary inventory	660,302	779,734
Hospitality inventory	1,501,127	625,080
Food and beverage inventory	463,451	414,151
	95,040,044	103,340,383
Less: Write-down of inventory	(836,111)	(425,920)
	94,203,933	102,914,463

Movement in the provision for inventory is as follows:

	30 June 2025	31 December 2024	30 June 2024
Balance at the beginning of the period/year	425,920	100,248	100,248
Provisions formed during the period/year	410,191	358,836	178,819
Provisions no longer required during the period/year	-	(33,164)	-
Balance at the end of the period/year	836,111	425,920	279,067

10. Trade receivables

	30 June 2025	31 December 2024
Due from customers	510,829,656	419,739,098
Income from inpatients	21,582,061	7,507,212
	532,411,717	427,246,310
Less:		
Impairment of customers' balances	(68,329,664)	(59,638,363)
	464,082,053	367,607,947

The income from inpatients comprises the revenues that have not been billed at the financial position date for their stay while the procedures of the medical services have not been completed. Such income is calculated net of the amounts collected in advance during the year of their stay.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

10. Trade receivables (continued)

The Company applies the EAS 47 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the payment profiles of customers over a period of 36 month before each balance sheet date and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Company has identified the GDP and the unemployment rate of the countries in which it sells its goods and services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors.

The credit loss allowance for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days that an asset is past due, with adjusting it.

30 June 2025				
Trade receivables	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
Current until less than 30 days overdue	0.2%	331,397,819	598,810	330,799,009
30 to 60 days overdue	2%	56,472,927	897,077	55,575,850
61 to 90 days overdue	4%	20,084,719	871,032	19,213,687
91 to 120 days overdue	9%	16,607,015	1,488,606	15,118,409
121 to 360 days overdue	24%	50,229,532	12,302,728	37,926,804
361 to 720 days overdue	40%	9,104,410	3,656,116	5,448,294
More than 720 days	100%	48,515,295	48,515,295	-
Total		532,411,717	68,329,664	464,082,053

31 December 2024				
Trade receivables	Loss rate	Gross carrying amount	Lifetime ECL	Net carrying value
Current until less than 30 days overdue	0.2%	285,709,864	469,197	285,240,667
30 to 60 days overdue	2%	35,965,673	661,995	35,303,678
61 to 90 days overdue	6%	12,863,612	752,692	12,110,920
91 to 120 days overdue	11%	15,861,540	1,794,083	14,067,457
121 to 360 days overdue	34%	28,488,559	9,581,359	18,907,200
361 to 720 days overdue	50%	3,946,333	1,968,308	1,978,025
More than 720 days	100%	44,410,729	44,410,729	-
Total		427,246,310	59,638,363	367,607,947

The movement in expected credit losses in the value of trade receivables is as follows:

	30 June 2025	31 December 2024	30 June 2024
Balance at the beginning of the period/year	59,638,363	40,969,078	40,969,078
Provisions formed during the period/year	10,698,610	22,185,829	8,683,513
Provision no longer required during the period/year	(2,007,309)	(3,516,544)	(166,321)
Ending balance at the end of period/year	68,329,664	59,638,363	49,486,270

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

11. Debtors and other debit balances

	30 June 2025	31 December 2024
Advances to suppliers	72,863,846	91,980,609
Prepaid expenses	26,035,674	22,392,202
Deposit with others	4,860,669	4,860,669
Withholding taxes	543,450	1,256,677
Employee's custodies	738,416	134,543
Other debtors	64,690,454	57,844,015
	169,732,509	178,468,715

12. Cash and cash equivalent

	30 June 2025	31 December 2024
Current accounts	28,917,044	34,069,087
Cash on hand	1,299,857	1,598,859
Term deposits	51,620,117	135,256,200
Deduct:		
Cash and cash equivalents impairment	(778,084)	(967,276)
	81,058,934	169,956,870

Movement in the impairment is as follows:

	30 June 2025	31 December 2024	30 June 2024
Balance at the beginning of the period/year	967,276	1,172,997	567,181
Formed during the period/year	260,347	573,408	881,100
No longer required	(449,539)	(779,129)	(110,705)
Ending balance	778,084	967,276	1,943,392

The time deposits item includes an amount EGP 51.620.117] on 30 June 2025 (2024: EGP 135.256.200) are denominated in local banks in US dollars and are payable within one from the date of deposit and are subject to a fixed annual return of 4.75%.

Current accounts deposited in Egyptian Pounds are subject to a fixed annual rate of 14.75% (2024: from 17% to 18%).

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

12. Cash and cash equivalent (continued)

For the purpose of preparation of the cash flow statements, cash and cash equivalents consist of:

	30 June 2025	30 June 2024
Cash and bank balances	81,837,018	37,817,883
Total	81,837,018	37,817,883

Classification within cash and cash equivalents

Term deposits are held with banks and presented as cash and cash equivalents if they have a maturity of three months or less from the date of deposit and are repayable with 24 hours' notice without loss of interest. Treasury bills listed under cash and cash equivalents have original maturities not exceeding three months from the date of acquisition and are easily convertible into known amounts of cash and are subject to insignificant risks of changes in value.

13. Loans

	30 June 2025		
	Current	Non-current	Total
Loans	73,650,000	294,600,000	368,250,000
Total	73,650,000	294,600,000	368,250,000
	31 December 2024		
	Current	Non-current	Total
Loans	67,835,068	271,340,272	339,175,340
Total	67,835,068	271,340,272	339,175,340

- On October 27, 2021, Cleopatra Hospital Company signed a medium-term loan contract with Ahli United Bank, with a total amount of 145 million Egyptian pounds, with a return of 0.65%, in addition to the lending rate announced by the Central Bank.
- On August 10, 2022, Cleopatra Hospital Company, Nile Badrawi Hospital Company, and Cairo Specialized Hospital Company signed an appendix to the loan contract from Ahli United Bank. The following are the most important terms of the contract:
- Increasing the financing amount to 285 million Egyptian pounds, and it will be divided among the companies as follows:
 - Cleopatra Hospital Company 45 million Egyptian pounds
 - Cairo Specialist Hospital Company 90 million Egyptian pounds
 - Nile Badrawi Hospital Company 150 million Egyptian pounds

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

13. Loans (continued)

- On May 10, 2023, the financing amount was redistributed among the companies as follows, with the maximum available financing amounting to EGP 340 million, and the aforementioned amount not to be exceeded at any time during the validity period of the contract.
- | | |
|-----------------------------------|-----------------------------|
| Cleopatra Hospital Company | 100 million Egyptian pounds |
| Cairo Specialist Hospital Company | 90 million Egyptian pounds |
| Nile Badrawi Hospital Company | 150 million Egyptian pounds |
- On 18 January 2024, Cleopatra Hospital Company, Nile Badrawi Hospital Company, and Cairo Specialist Hospital Company signed an appendix to the loan contract from Ahli United Bank to increase loan amount to 740 million EGP and reallocate the loan between companies to be as follows
- | | |
|-----------------------------------|-----------------------------|
| Cleopatra Hospital Company | 500 million Egyptian pounds |
| Cairo Specialist Hospital Company | 90 million Egyptian pounds |
| Nile Badrawi Hospital Company | 150 million Egyptian pounds |
- On 17 April 2024, Cleopatra Hospital Company, Nile Badrawi Hospital Company, and Cairo Specialist Hospital Company signed an appendix to the loan contract from Ahli United Bank to reallocate the loan between companies to be as follows
- | | |
|-----------------------------------|-----------------------------|
| Cleopatra Hospital Company | 400 million Egyptian pounds |
| Cairo Specialist Hospital Company | 90 million Egyptian pounds |
| Nile Badrawi Hospital Company | 250 million Egyptian pounds |
- The purpose of the loan is to finance and/or refinance the capital needs and renovation of the group's hospitals starting from 2021, including medical equipment, medical beds, medical and non-medical furniture, as well as internal development of movables (finishes, electromechanical equipment, and power station).
- The validity of this contract begins for a period of six years and six months from the date of signing the financing contract on 27 October 2021, with the group being granted a grace period of a maximum of one year and six months ending on 31 December 2023, and a grace period (applied to repayment of the principal) of one year and six Months ending on 31 January 2024, and in the event that the entire amount of financing is not withdrawn during the aforementioned grace period, the unwithdrawn part will be automatically cancelled and the bank is not obligated to lend the group any amounts other than what has been withdrawn from the financing amount, with the exception of the third tranche for Cleopatra Hospital Company, amounting to 400 million Egyptian pounds, the withdrawal period is two years starting from the date of signing the contract and a grace period of 18 months from the date of the first withdrawal from the tranche.
- The group is committed to repaying the total financing amount in 20 quarterly instalments, with the first instalment starting on 31 December 2024.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

13. Loans (continued)

Financial ratios

According to the terms of the contract, the company is committed to achieving the following financial ratios:

- The financial leverage of the group should not exceed 0,7 and that of the Nile Badrawi Hospital Company should not be less than 1.
- The debt service ratio should not be less than 1.3.
- The liquidity ratio should not be less than 1.

The loans contain certain covenants. A future breach of covenants may lead to renegotiation. The covenants are monitored by management, in case of potential breach, actions are taken by management to ensure compliance. During 2024 till 30 June 2025, there has not been any non-compliance observed for any of the covenants.

14. Banks overdraft

	30 June 2025	31 December 2024
Banks overdraft	328,009,587	302,160,797

The company obtained total credit limits in the form of overdrafts from banks in order to finance working capital at an interest rate of 0.1% in addition to the announced lending rate from the Central Bank. The total available credit limits amounted to 330 million EGP and the withdrawn value of these credit limits in 30 June 2025 equals EGP 328,009,587 (EGP 302,160,797 in 31 December 2024).

15. Trade and Other Payables

	30 June 2025	31 December 2024
Suppliers and notes payable	301,236,466	211,027,688
Accrued expenses	199,903,216	166,851,265
Social insurance	4,807,849	4,141,753
Other creditors	86,892,108	20,045,667
	592,839,639	402,066,373

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

16. Lease liabilities

The company has applied the new Egyptian accounting standard EAS 49 “Lease contracts” on 1 January 2021. The company has applied the standard using the modified retrospective approach, and the comparative figures have not been restated.

The weighted average incremental borrowing rate applicable to lease commitments recognized on 1 January 2021 was 11.15%.

	30 June 2025	31 December 2024
Undiscounted		
During period/year	14,223,661	12,380,013
More than period/year	39,784,721	42,428,369
	54,008,382	54,808,382
The present value of the lease obligations is as follows:		
During period/year	14,223,661	12,380,013
More than a year	27,784,400	30,526,476
Balance	42,008,061	42,906,489
	30 June 2025	31 December 2024
Lease Liabilities were presented as follows:		
Lease liabilities shown as at 31 December 2024	42,906,489	49,943,749
Adjustments period/year	-	140,149
Additions during period/year	2,966,545	-
Add: Interest formed period/year	2,755,344	5,492,039
Deduct: Payments period/year	(6,620,317)	(12,669,448)
Lease liabilities at 30 June 2025	42,008,061	42,906,489

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

17. Revenue

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Surgeries revenue	221,125,089	177,785,403	119,155,141	91,045,598
Accommodation and medical supervision revenue	280,741,675	189,068,739	142,667,862	97,589,581
Laboratories revenue	136,367,471	100,431,113	74,772,191	50,564,726
Outpatient clinics revenue	115,199,789	93,503,846	60,508,297	45,059,341
Radiology revenue	110,282,252	73,828,124	57,889,886	37,533,568
Service charge revenue	93,609,467	72,765,415	49,178,415	37,467,813
Cardiac catheterization revenue	77,541,928	66,810,241	45,119,851	35,294,569
Pharmacy revenue	99,587,274	64,954,717	52,457,563	31,982,548
Emergency revenue	66,605,563	49,294,722	33,536,715	25,866,180
Physiotherapy revenue	18,707,819	15,289,070	9,351,389	6,342,645
Cardiac tests revenue	18,293,801	10,755,467	9,978,632	5,094,324
Endoscopy revenue	12,628,890	8,489,072	7,031,818	4,503,729
Dentistry revenue	8,088,939	6,309,383	4,470,737	3,305,099
Revenues from other departments	16,277,223	11,373,403	8,937,137	5,348,168
	1,275,057,180	940,658,715	675,055,634	476,997,889

* “Service charge” does not represent a separate performance obligation but is a surcharge at a fixed percentage rate applied to all revenue streams except for sale of medicines.

All types of revenue are recognized at a point in time except accommodation and medical supervision are recognized over time.

Timing of revenue recognition (for each revenue stream) is as follows:

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
At a point in time	994,315,505	751,589,976	532,387,772	379,408,308
Over time -Accommodation and medical supervision revenue	280,741,675	189,068,739	142,667,862	97,589,581
	1,275,057,180	940,658,715	675,055,634	476,997,889

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

18. Cost of revenue

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Medical and pharmaceutical supplies	274,166,755	173,824,902	145,639,462	90,750,189
Salaries, wages and benefits	185,069,652	135,539,812	93,444,235	68,532,626
Doctors' fees	154,370,277	130,602,098	82,034,307	64,043,799
Maintenance, spare parts and energy expenses	27,585,711	23,659,298	13,772,155	12,578,552
Fixed assets depreciation	29,377,835	19,493,111	18,507,646	10,210,058
Consumables costs	15,606,613	14,830,634	7,899,075	8,250,654
Outsourcing services	16,542,844	13,447,139	8,324,595	6,736,393
Rents	6,101,132	5,027,156	3,741,888	3,017,682
Lease amortization	852,540	656,378	452,233	328,189
Other expenses	17,802,969	20,292,212	10,938,719	9,875,302
	727,476,328	537,372,740	384,754,315	274,323,444
Less: Group's share of the Company's expenses	(12,326,414)	(6,492,667)	(5,770,981)	(2,957,576)
	715,149,914	530,880,073	378,983,334	271,365,868

19. General and administrative expenses

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Salaries, wages and benefits	174,394,378	113,919,235	88,307,790	69,091,174
Professional and consulting fees	7,595,507	8,158,227	3,536,120	4,788,074
Fixed assets depreciation	7,083,965	8,155,165	3,569,969	4,271,785
Outsourcing services	11,982,650	7,912,611	6,211,670	3,680,520
Lease amortization	3,682,758	3,729,954	1,836,308	1,864,977
Maintenance, spare parts and energy expenses	3,615,143	2,693,206	1,854,089	1,541,170
consumables costs	1,066,093	1,172,667	510,558	584,898
Other expenses	46,003,433	35,647,106	25,269,031	18,487,528
	255,423,927	181,388,171	131,095,535	104,310,126
Less: Group's share of the Company's expenses	(90,653,251)	(52,998,437)	(45,072,791)	(33,047,300)
	164,770,676	128,389,734	86,022,744	71,262,826

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

20. Net impairment losses on financial assets

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Trade receivables impairment	8,691,300	8,517,192	2,864,993	4,921,390
Cash in bank impairment	(189,192)	770,395	(372,478)	346,577
Total	8,502,108	9,287,587	2,492,515	5,267,967

21. Earnings per share

The basic share of the profit for the period is calculated by dividing the net profit for the period attributable to the company's shareholders by the weighted average number of shares outstanding during the period after excluding employee dividends.

	Six months ended 30 June		Three months ended 30 June	
	2025	2024	2025	2024
Distributable profit	249,858,370	189,967,085	137,936,405	89,059,982
Weighted average number of basic share	1,441,509,083	1,441,509,083	1,441,509,083	1,441,509,083
Weighted average number of basic shares for employee dividends.				
Weighted average number of diluted shares	1,441,509,083	1,441,509,083	1,441,509,083	1,441,509,083
Basic Earnings per share profit for the period	0.17	0.13	0.10	0.06
Diluted Earnings per share profit for the period	0.17	0.13	0.10	0.06

The weighted average number of shares is adjusted to take into account the shares held under the bonus and incentive scheme for employees, directors and executive board members.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

22. Related parties from / to transactions

During the period/ year the Company made transactions with certain related parties. The Balances with related parties at the financial statements date as well as the transactions during the year were as follows:

Balances of financial position

(Related parties)	Nature of transaction	Transaction value	Balance due from related parties 30 June 2025	Balance due from related parties 31 December 2024
CHG SKY Hospital	Expenses on behalf of the company	70.892.302	86,762,112	15,869,810
Cleopatra Haven Company	Expenses on behalf of the company	13.422.115	98,885,034	85,462,919
CHG for Medical Service (Subsidiary)	Payments on behalf of the company	2.450.810	50,558,780	48,107,970
CHG Pharma for Pharmacies Management (Subsidiary)	Payments on behalf of the company	476.004	3,945,995	3,469,991
Nile Badrawi Hospital Company (Subsidiary)	Payments on behalf of the company	1,568,027	4,188,468	2,620,441
Other parties	Expenses on behalf of related parties	-	256,190	256,190
			244,596,579	155,787,321
(Related parties)	Nature of transaction	Transaction value	Balance due (to) related parties 30 June 2025	Balance due (to) related parties 31 December 2024
Al Shorouk Hospital (Subsidiary)	Payments on behalf of the company	(57.656.362)	(153,874,380)	(96,218,018)
CHG for Hospitals management (Subsidiary)	Payments on behalf of the company	(1.579.871)	(17,630,452)	(19,210,323)
New Bedaya for management of medical centres and Hospitals	Payments on behalf of the company	(3,79 8,785)	(33,864,120)	(30,065, 335)
Cairo Specialised hospital (Subsidiary)	Payments on behalf of the company	(90,301,691)	(92,009,881)	(1,708,190)
			(297,37 8,831)	(147,201,866)

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

22. Related parties from / to transactions (continued)

- During 2017, Cleopatra Hospital Company signed an agreement with its subsidiaries. Under this contract, the company distributes the costs of joint activities to the group companies according to the percentages related to the revenues achieved by each company.
- This agreement has been approved by the boards of directors of the group companies and their general assemblies.
- The transactions with the related parties are the Group's dealings with the parent company, whether by buying, selling or exchanging services. Prices, policies and conditions related to these operations are approved by the Group's management and are on the same basis as dealing with others.

23. Capital commitments:

Capital commitments at financial year end, which are not yet due, amounted to EGP 3.326.776 (31 December 2024: EGP 25,000), Which represents capital commitments to purchase fixed assets and projects under construction,

24. Subsequent events

The Company's Extraordinary General Assembly, held on June 17, 2025, approved, by a majority of 99.99% (988,980 shares) and 0.01% (100,067 shares) of the total votes present, the extension of the employee benefits and incentives for a new period of seven years, starting July 1, 2025, under the same terms and conditions, with the addition of some amendments and clarifications as stated in the bylaws.

The stock sale agreement was also approved with the same amended terms and conditions included in the system, in light of the terms and conditions included in the disclosure report in accordance with Article No. 50 of the rules for listing and delisting securities, published on the Egyptian Stock Exchange screens on June 18, 2025.

CLEOPATRA HOSPITAL COMPANY “S.A.E.”

Notes to the interim condensed separate financial statements For the six months period ended 30 June 2025

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

25. Tax position

1: Corporate Income Tax

- The inspection was completed up to December 31, 2019, and the settlement was fully made.
- For the year 2020 inspection, paid and settlement in progress.
- For the years 2021 and 2022 , the inspection is currently in progress.
- The tax returns for the years 2023 , 2024 were submitted within the legally prescribed deadlines.

2: Payroll Taxes

- The inspection was completed up to December 31, 2019, and the settlement was fully made.
- The inspection was completed for 2020, 2021,2022 and the settlement was fully made.
- The inspection for the year 2022 was completed, and the principal amount was paid.
- Payroll tax settlements and Form 4 salary statements for 2023 , 2024 were submitted within the legally prescribed deadlines.

3: Stamp Duty

- The inspection was completed up to July 31, 2006, and the payment was made.
- The inspection was completed up to the year 2020, and the payment was made, with the settlement currently in progress.
- Inspection on progress for 2021,2022

4: Value Added Tax (VAT)

- The inspection was completed up to the year 2022.
- Monthly returns are submitted within the legal deadlines.